IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
![]() |
- IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.
- Maximum dose reached with no dose-limiting toxicities observed.
- TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma.
MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 /PRNewswire/ --...





